Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is another worthless pump. Please provide evidence of what you hope for, then you might be believed.
Look at the website
Prana Alzheimer's disease data features at world leading conference
July 27, 2016
The volume spike didn't occur until yesterday, Aug. 8.
Look again. The dump part of pump/dump is occurring, as always. Maybe a few are recovering losses.
Number 1 on the AGM agenda could be the nasdaq noncompliance issue.
Inversor, sorry that you see my posts as negative. No, I am not yet a shareholder. After the usual investigation, I wondered why no corporation had bought out or at least offered partnership over the years. After reviewing the regulatory filings, there are still questions. The financials are pretty clear. I did considerable reading, including iHub.
As you know , I started posting here on October 1 and wrote 15 posts during these past seven weeks. This is #16. Half of those posts were in this week, goaded on by your arrogant friend. I have little time for such nonsense.
I see my posts as objective, not negative. But this week I made an easy decision. I will not be posting nor reading here in the future.
Can Patients Scoop Clinical Trial Results?
http://propthink.com/can-patients-scoop-clinical-trial-results/3749
There are some interesting examples of neurological anecdotal stories being leaked before final official data has been released. This is not a good trend.
You really need me to tell you which science(sic) has the best shot against Huntington's and Alzheimer's? I don't have a favorite but have always liked all science.
Now listen. You have displayed a naive distorted understanding of my posts a few times. Then, you reply with distorted "questions" and remarks which have little to do with the subject and do not deserve a response from a thinking person. I'd like to think that you are posting in good faith. IMO, you are not doing Prana and shareholders much good with your slanted presentation. Consider looking at all aspects and if they can be improved. It's the scientific way.
At your request, I'd suggest the following science which may "have a shot against Huntington's and Alzheimer's". Read carefully this time. Take your pick, or try a combination:
Neuroscience, biochemistry, biotechnology, epigenetics, genomics, immunogenetics, microbiology, neurobiology, pharmacogenetics, pharmacology, and proteomics.
Don't forget the scientific method,logic and statistics. Some bioethics may help you too.
Please do not reply.
The FDA would not find it necessary to reply to such "questions".
Simple reading comprehension is helpful. Get some sleep.
My last post of the day.
There are those who have been thoroughly educated in science and business, and there a few who play at science and business online.
Unfortunately this can hurt the innocent who do not recognize the difference.
Greed and misplaced egoism play a large part.
Kadaicher, the important factor in this Phase II trial is that the only patient who has completed 6 months of dosing has had no adverse effects. We don't know if he/she was receiving PBT2 or placebo. We don't know if this one patient plus potentially 99 others can achieve and maintain safety and efficacy for the 15-20 year period which is the average length of this terrible disease. That is why other Huntington's trials have not yet achieved success.
I would advise you to realize that constant name-dropping, including that related to Harvard, doesn't mean much. Harvard is also involved in a Rube Goldberg type study of Alzheimer's as refered to in IV post 231:
>Pascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement. Their improvement was significantly more than the average seen in patients taking just medication, he said.<
This certainly is not a diss of the esteemed Harvard. Just understand that there's a big world out there where scientists are quietly making progress and patient investors know that this research isn't a get-rich quick field.
IMHO, sincerely, Prana should be looking for a partner with deep pockets who can provide funding and move trials along. This is easier said than done. It would avoid situations such as the gap since the end of the Alzheimer's trial which was "completed" in 2008. It may also attract more investors who are discouraged by the repeated printing of new shares with resulting dilution.
Good luck.
Now, now. I did not say "many" years. It takes more than six months to prove that a genetic disease such as Huntington's will show the desired efficacy, especially from an early stage.
One other thing to consider is the enormous amount of finances that are necessary. Printing additional shares every few months can't go on forever. The market has recognized this.
It's good that the study personnel seem to be working seriously to complete enrollment of 37 more patients to meet the goal of 100. Hopefully more neurologists will come around and refer patients for this particular Huntington clinical trial.
It was also pointed out that it may be possible to progress to a Phase III trial if the current small trial shows promissing results when it concludes next year. A Phase III study would of course require many hundreds of patients and years to evaluate patients' response.
Prana has the opportunity to learn from the efforts of many others. An interesting, but incomplete, history of Alzheimer's research from the WSJ:
http://online.wsj.com/article/SB10000872396390443624204578060941988428604.html?mod=WSJ_hpp_LEFTTopStories
One of many hopes for Alzheimer's(from Reuter's):
Israel's Neuronix offers new Alzheimer's treatment
4:16am EST
(In paragraph 2 of Oct. 24 story, company corrects to say that in Singapore, device is approved for clinical trial use and its application for registration of the product is under evaluation, not that device is approved for commercial use)
* Combines electromagnetic stimulation with cognitive training
* Approved for use in Europe, Israel, Singapore
* Neuronix explores options to raise money including possible IPO
By Tova Cohen
TEL AVIV, Oct 24 (Reuters) - Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer's disease, expects the system to be approved by the U.S. Food & Drug Administration in late 2014.
The device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries. In Singapore it is approved for clinical trial use and the application for registration of the product is still under evaluation.
"You stimulate the brain on a biological level as well as on a cognitive level," Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.
The device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer's patients who suffer from dementia but are not totally dependent.
The system is in trials at Harvard Medical School/Beth Israel Deaconess Medical Centre. Patients are treated for one hour a day, five days a week over six weeks.
"We see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again," Baror said. "If out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it's a lot."
According to Alvaro Pascual-Leone, director of the hospital's Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.
"The application in Alzheimer's disease and in combination with cognitive training is novel," Pascual-Leono said in a phone interview from Boston.
About 20 percent of patients experience a mild headache but there are no long-term negative effects, he said.
Pascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement. Their improvement was significantly more than the average seen in patients taking just medication, he said.
The study's results will be submitted for publication in the coming weeks and a follow-up study on 30 patients is planned.
Neuronix received European approval several months ago and has installations in the UK and Germany. In Israel, a few dozen patients are being treated with the device.
The U.S. trials are expected to run till the end of 2013. Neuronix is also running a trial in Israel for pre-Alzheimer's patients.
The company expects to sell half a dozen systems in the second half of 2012 and three dozen in 2013. In Israel, the treatment costs $6,000.
"Our target for becoming profitable is in parallel to entering the U.S. market around 2015," Baror said.
Neuronix has raised $8 million from private individuals as well as in grants from the Israeli Chief Scientist's Office and is exploring options to raise more money in the coming year, including the possibility of going public. (Reporting by Tova Cohen; editing by Stephen Nisbet)
© Thomson Reuters 2011. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.
Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to colleagues, clients or customers, use the Reprints tool at the top of any article or visit: www.reutersreprints.com.
Link for Huntington clinical trial sites. Sites are listed near bottom.
http://clinicaltrials.gov/ct2/show/study/NCT01590888?spons=%22Prana+Biotechnology+Limited%22&spons_ex=Y&rank=2&show_locs=Y#locn
Slow enrollment is troubling. Surely at least one of the sites should be fully enrolled now after 6 months.
It would be good to know if the problem is due to hesitance of patients, families, or referring physicians. Hopefully the situation is being investigated by Prana.
Well. So the FDA and the EMEA and the ROW are not involved in the Alzheimer's clinical testing. I should have done more research earlier.
Thank you for your kind reply and for the links.
Clinicaltrials.gov shows that none of the Huntington PBT2 study trial sites are fully enrolled yet. Initial study plans were for 100 patients and six-month dosing period. The study began in April 2012 with plans for final data collection by Oct. 2013. The clinicaltrials.gov site shows their last update as Oct. 5, 2012.
Is it accurate to expect that enough patients will be eventually available for a sufficiently-powered study?
Also, the only trial shown for an Alzheimer's PBT2 study was started in 2007 and completed in Jan. 2008. There is no information about a current Alzheimer's study on the site.
Fun and games at the close. It's called "painting the tape". Be careful tomorrow. From NASDAQ:
Real Time Stock Quotes: Prana Biotechnology Ltd (PRAN)
10/4/2012 Market Closed
PRAN's NASDAQ Last Sale
2.35 0.16 7.30%
NLS Volume
46,586
NASDAQ Official Price
Open Price/Date
Oct 04, 2012$ 2.19
Oct 04, 2012 Close Price/Date
$ 2.35
Oct 04, 2012
Share Volume
16:00:01 $ 2.35 1,200
15:59:54 $ 2.3299 100
15:57:07 $ 2.334 1,100
15:56:30 $ 2.33 100
15:56:30 $ 2.35 500
The expected results turned out to be disappointing today as the PPS fell 4.22% down to a close of $2.27. Volume was also disappointing. Was the $6 million private placement felt to be insufficient for the long haul ahead? Did Dr. Tanzi's audience not hear what they wanted to hear, or is it too early for them to make a judgment?
Chins up.